Opendata, web and dolomites


Assessing the feasibility of MT-011, a first-in-class drug to treat glaucoma and other neurodegenerative diseases via a breakthrough mechanism-of-action

Total Cost €


EC-Contrib. €






 SA-VOIR project word cloud

Explore the words cloud of the SA-VOIR project. It provides you a very rough idea of what is the project "SA-VOIR" about.

voir    deterioration    30    peripheral    tension    world    upfront    optimization    inhibits    causes    critical    inhibiting    assay    inherently    size    manner    sa    de    risked    dysregulation    investment    implicated    strengthen    inhibit    irreverisble    affinity    blindness    glaucoma    people    nanomolar    pharmaceutical    followed    drugs    011    business    payments    commercialize    attract    trials    vash    assets    indicated    pharmaceuticals    plan    guide    black    neurogenerative    enzyme    candidate    vision    prominent    aside    proprietary    pfizer    santen    small    drug    family    act    broad    newly    stage    receive    continued    hyperactivated    million    biochemical    applicable    diagnosed    disorder    report    parkinson    elucidated    subtype    treatments    start    applicability    diseases    normal    alzheimer    deal    licensing    biotechnological    outline    components    eye    40m    milestone    tunnel    form    house    total    documents    halt    imminent    molecule    mt    seeing    clinical    patients    neurodegenerative    companies   

Project "SA-VOIR" data sheet

The following table provides information about the project.


Organization address
address: 66 RUE DU CLAOUS
postcode: 34190
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MT ACT FR (CAZILHAC) coordinator 50˙000.00


 Project objective

Glaucoma is the world's leading cause of irreverisble blindness, affecting 20 million people in Europe and the US. Known as the Alzheimer’s of the eye, glaucoma is a neurodegenerative disorder that causes deterioration in peripheral vision. Affected patients report ‘seeing through a black tunnel’. Treatments to halt vision loss are available however, they are only applicable for the ‘high tension glaucoma’ subtype. For those diagnosed with ‘normal tension', which comprises over 30% of glaucoma patients, no treatments are available, and vision loss is imminent. New drugs that inhibit VASH, a newly elucidated enzyme that is hyperactivated in many neurogenerative diseases, have potential to address this need.

We at MT-act are a biotechnological start-up who have identified a family of VASH-inhibiting small molecule drugs. Using an in-house proprietary biochemical assay followed by lead optimization, we have identified MT-011, which inhibits VASH with nanomolar affinity, as our lead candidate. Aside from glaucoma, VASH dysregulation is also implicated in other prominent neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Our assets therefore have an inherently broad applicability.

We aim to develop MT-011 up to the stage of Phase 1 clinical trials, upon which we aim to commercialize the drug via a licensing deal with a pharmaceutical partner. We will then receive upfront and milestone payments with a estimated total deal size of €40M. We are currently in discussion with world-leading pharmaceutical companies Pfizer and Santen Pharmaceuticals, who have already indicated interest in our drugs.

In SA-VOIR, we aim to strengthen the business case for MT-011 and to outline a detailed technical plan for its continued development. These documents will not only guide us in developing MT-011 towards Phase 1 trials in an effective and de-risked manner, it will also form critical components of a business plan that we will use to attract further investment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SA-VOIR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SA-VOIR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

HUD (2018)


Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  


Specialized Help from Be My Eyes – harnessing technology to connect companies directly with their blind and visually impaired users

Read More